Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

Before Hims & Hers' commercial even aired ... "help-seeking" advertisements." The day after the ad for Hims & Hers' aired during the Super Bowl, on Feb. 10, Novo Nordisk, the maker of Ozempic ...

And the company’s share price is up about 15% since just before the Super Bowl, giving it a valuation of more than $10 billion. Hims & Hers may be taking risks and pushing the regulatory ...

Hims & Hers has shown impressive revenue growth ... followed by 0% for the 12 months after that. For years 3, 4 and 5 we assume a growth rate of 20-25%. We assume that Hims’ weight loss business ...

Hims & Hers makes its Super Bowl commercial debut in 2025 with a spot for the telehealth company's weight loss medications. Set to the "This Is America" by Childish Gambino (Donald Glover), the ...

Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the ...

Telehealth company Hims & Hers Health is fighting back after the drug industry’s main lobbying group called out its first Super Bowl ad as “misleading” and in potential violation of ...

Super Bowl commercial in which telehealth company Hims & Hers hyped up compounded weight-loss drugs, which aren’t FDA-approved. The fallout has become political, too. Two days before the Super ...

After telehealth brand ... The “Check before you inject” ad specifically calls out compounded medications, which is the type that Hims & Hers manufactures and is not FDA approved.